Specific high-quality fat structure cholecystokinin CCK releasing agent and preparation and application thereof in controlling body weight and preventing and treating overweight or obesity

Through the combination and preparation method of specific high-quality fatty acids, cholecystosis CCK release agent is formed, which solves the side effects and instability of weight control and obesity treatment methods in the prior art, and achieves safe and effective weight management and blood lipid regulation .

CN118902101APending Publication Date: 2024-11-08ZHONGKE YOUPIN (TIANJIN) TECH DEV CO LTD +2
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202311450313.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-11-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is a lack of healthy and safe products for controlling weight, preventing and treating overweight and obesity in the prior art, and the existing methods have side effects or unstable effects.

Method used

Using a combination of specific high-quality fat structures, including medium-chain saturated fatty acids, long-chain saturated fatty acids and long-chain unsaturated fatty acids, the cholecystosis CCK release agent is formed through specific ratios and preparation methods, and is used to increase cholecystosis Secretion, regulate appetite and weight.

Benefits of technology

It significantly increases the secretion of cholecystosis, regulates the intake, reduces the content of triglycerides and free fatty acids in the body, and reduces body weight. The preparation method of liquid dosage forms improves stability and reduces the floating of fat globules.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902101A_ABST
    Figure CN118902101A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of health-care products, and particularly relates to a specific high-quality fat structure cholecystokinin CCK releasing agent and preparation and application thereof in controlling body weight and preventing and treating overweight or obesity. The releasing agent comprises medium-chain saturated fatty acid, long-chain saturated fatty acid and long-chain unsaturated fatty acid; wherein the medium-chain saturated fatty acid is saturated fatty acid with the carbon atom number of 6 to 12; the long-chain saturated fatty acid is saturated fatty acid with more than 12 carbon atoms; the long-chain unsaturated fatty acid is unsaturated fatty acid of which the carbon atom number is greater than 12. The cholecystokinin CCK releasing agent is prepared by adopting a high-quality fat structure, can increase the secretion of cholecystokinin, regulate the food intake, reduce the food intake, increase the satiety and inhibit the appetite, can reduce the content of triglyceride in the body, reduce the content of free fatty acid, obviously and scientifically reduce the body weight, and has a good effect on preventing and treating the cholecystokinin. The method can be applied to the fields of controlling body weight and preventing and treating overweight and obesity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of health care products, and specifically relates to a specific high-quality fat structure cholecystokinin (CCK) releaser and its preparation and application in controlling body weight, preventing and treating overweight or obesity. Background Art

[0003] Current methods of weight control include medication, dehydration, high-fiber foods, liposuction, etc. For example, although surgical and medication weight loss can quickly achieve weight loss results, they have obvious side effects and can cause irreversible damage to the body; other methods have side effects such as vomiting, abdominal pain and diarrhea, weakness, malnutrition, weight regain, etc. There is currently a lack of healthy and safe products for controlling weight and preventing overweight and obesity.

[0004] One possible target for combating the obesity epidemic is cholecystokinin. CCK is a peptide hormone. Cholecystokinin (CCK) is a brain-gut peptide. As a gastrointestinal hormone, it participates in the regulation of gastrointestinal function, stimulates pancreatic enzyme secretion and synthesis, enhances bicarbonate secretion and gastric emptying, stimulates gallbladder contraction and relaxation of the sphincter of Oddi, and can also excite liver bile secretion, regulate small intestine and colon motility, and act as a satiety signal to suppress appetite. It is the main physiological factor in peripheral food intake regulation; as a central neurotransmitter, it interacts with other food-related transmitters and participates in central food intake regulation. At the same time, it also affects the body's long-term energy balance and participates in weight regulation.

[0005] At present, CN201380047772 discloses a composition for promoting the secretion of cholecystokinin, which contains acrylic acid and / or the following unsaturated aldehydes as effective ingredients. CN201610163411 discloses the use of cholecystokinin receptor inhibitor Devazepide in the preparation of anti-fibrosis drug preparations. Cholecystokinin receptor inhibitor Devazepide can effectively inhibit and kill myofibroblasts closely related to human tissue and organ fibrosis, and can also inhibit the contractile ability of myofibroblasts. However, in the field of weight control, prevention and treatment of overweight and obesity, there is no research on promoting the release of cholecystokinin (CCK) through a specific high-quality fatty acid compatibility structure. Summary of the invention

[0006] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a specific high-quality fat structure cholecystokinin (CCK) releaser and its preparation and application in controlling body weight, preventing and treating overweight or obesity.

[0007] To achieve the above object, the technical solution adopted by the present invention is:

[0008] A cholecystokinin (CCK) releaser with a specific high-quality fat structure, comprising medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids; wherein the medium-chain saturated fatty acids are saturated fatty acids with 6 to 12 carbon atoms; the long-chain saturated fatty acids are saturated fatty acids with more than 12 carbon atoms; and the long-chain unsaturated fatty acids are unsaturated fatty acids with more than 12 carbon atoms.

[0009] The medium-chain saturated fatty acids are a combination of C6:0, C8:0, C10:0 and C12:0; the long-chain saturated fatty acids are a combination of C14:0, C16:0 and C18:0; and the long-chain unsaturated fatty acids are a combination of C18:1, C18:2 and C18:3.

[0010] The medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids are derived from one or a combination of coconut powder, soybean oil, peanut oil, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract, and fish oil.

[0011] The medium-chain saturated fatty acids, long-chain saturated fatty acids and long-chain unsaturated fatty acids are derived from coconut powder, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract and fish oil.

[0012] The mass ratio of the coconut powder, medium chain triglyceride, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract and fish oil is 28-29.4:39.8-46:5:

[0013] 3-4:15-19.5:0.2-2.5:0.5-0.6:0.6:0-1; preferably 29.4:44.3:5:4:15:0.2:0.5:0.6:0.

[0014] The mass ratio of the medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids is 57.79±1-73.95±1:15±1-19±1:10.73±1-23.40±1; preferably, the mass ratio of the medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids is 73.95±1:15±1:10.73±1.

[0015] The mass ratio of C6:0, C8:0, C10:0 and C12:0 in the medium-chain saturated fatty acids is 0.35±1-0.5±1:26±1-31.98±1:21±1-26.86±1:10.29±1-14.73±1; preferably 0.38±1:31.98±1:26.86±1:14.73±1;

[0016] The mass ratio of C14:0, C16:0 and C18:0 in the long-chain saturated fatty acids is 3.5±1-4.93±1:6.39±1-10.85±1:3.7±1-5.8±1; preferably 4.93±1:6.39±1:4±1;

[0017] The mass ratio of C18:1, C18:2 and C18:3 in the long-chain unsaturated fatty acids is 3.02±1-9±1:2.76±1-7.9±1:2.57±1-6.5±1; preferably 3.02±1:2.76±1:4.95±1.

[0018] The hemagglutination activity of red blood cells is 584149-972000U / 100g, the α-amylase activity is 10300-24388HUA / 100g; the secretion of cholecystokinin is increased by 35%-45%, preferably by 40%-45%, and preferably by 45%.

[0019] The present invention also includes a method for preparing the specific high-quality fat structure cholecystokinin (CCK) releaser, including preparing two dosage forms: powder and liquid;

[0020] Preferably, the preparation into a powder dosage form comprises the following steps:

[0021] S11: Medium chain triglycerides, safflower seed oil, linseed oil, and coconut oil are microencapsulated powders that are formed into powders containing 70% / 50% fat content or are embedded as a whole into powders through a secondary microencapsulation process;

[0022] Preferably, the preparation process of the microencapsulated powder is as follows: adding antioxidants and stabilizers to medium-chain triglycerides, safflower oil, linseed oil, and coconut oil, heating and mixing at 45°C-50°C to obtain a mixed solution A; adding the aqueous wall material to purified water, dissolving at 40-50°C to obtain a mixed solution B, adding the mixed solution A to the mixed solution B, emulsifying with a shearing machine; homogenizing at 20-40MPa for 2-3 times; and spray drying to obtain;

[0023] Preferably, the aqueous wall material is one of vegetable protein, casein, sodium caseinate, modified starch, gelatin, and whey protein;

[0024] S12: mixing the microencapsulated powder obtained in S11 with coconut powder, oligofructose, wolfberry powder, and white kidney bean extract for 40 min;

[0025] Preferably, the preparation into a liquid dosage form comprises the following steps:

[0026] S21: premix purified water with protein, coconut powder, oligofructose, wolfberry powder and white kidney bean extract at 30°C-35°C and stir for 15-20 minutes;

[0027] S22: adding medium chain triglycerides, safflower seed oil, linseed oil, coconut oil, or fish oil to the mixture obtained in S21, mixing at 40-45° C. and 600 r / min for 20 min;

[0028] S23: Raise the temperature to 65°C, add the stabilizing system, and stir for 10-15 minutes;

[0029] S24: pre-sterilization 85-90℃, 30s;

[0030] S25: homogenization 280 bar, 55 ° C;

[0031] S26: Add other auxiliary materials, vitamins and minerals to make up the volume;

[0032] S27: high temperature sterilization, 141℃-145℃, 4-6s;

[0033] S28: Homogenization 100bar;

[0034] S29: Aseptic filling, or sterilization at 110-121℃, 15-30min;

[0035] The present invention also includes an application of the cholecystokinin (CCK) releaser with a specific high-quality fat structure, which is applied to controlling body weight, preventing and treating overweight and obesity; specifically, it is applied to health products, functional foods, sports nutrition foods, and special medical formula foods.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] The cholecystokinin CCK releaser in the present application is formulated with a high-quality fat structure, which can increase the secretion of cholecystokinin, regulate food intake, reduce food intake, increase satiety, and suppress appetite. At the same time, it can reduce the triglyceride content in the body, reduce the content of free fatty acids, and significantly and scientifically reduce body weight. It can be used in the fields of weight control, prevention and treatment of overweight and obesity. Especially for the preparation method of liquid dosage form, the special preparation method of cholecystokinin CCK releaser increases the stability of the liquid dosage form and reduces the floating of fat globules. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The composition diagram of the cholecystokinin CCK releaser (hereinafter referred to as releaser) with a specific high-quality fat structure of Example 1 of the present invention;

[0039] Figure 2The processing technology of the release agent of Example 6 of the present invention is a comparison diagram of the distribution state of fat globules;

[0040] Figure 3 The processing technology of the release agent of Example 7 of the present invention is a comparison diagram of the distribution state of fat globules;

[0041] Figure 4 A comparison chart of the secretion of cholecystokinin (CCK) in rat blood by the release agent of the embodiment of the present invention;

[0042] Figure 5 This is a comparison chart of triglyceride (TG) content in rat blood of the release agent of the present invention;

[0043] Figure 6 This is a comparison chart of the cholesterol (TC) content in rat blood of the release agent of the present invention;

[0044] Figure 7 This is a comparison chart of the low-density lipoprotein (LDL-C) content in rat blood of the release agent of the present invention;

[0045] Figure 8 This is a comparison chart of alanine aminotransferase (ALT) activity in rat blood of the release agent of the present invention;

[0046] Fig. 9 This is a comparison chart of aspartate aminotransferase (AST) activity in rat blood of the release agent of the embodiment of the present invention. DETAILED DESCRIPTION

[0047] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and the best embodiments.

[0048] There are many ways to name fatty acids, one of which is based on the carbon atom numbering of the fatty acid. The farthest methyl carbon is also called the ω-carbon atom. The carbon atoms of the fatty acid are counted from the carbon atom farthest from the carboxyl group, that is, the farthest methyl carbon atom ω, and are numbered alphabetically as ω-1, ω-2, ω-3, etc. The position of the unsaturated bond is represented by ω-. For example, oleic acid (18:1, ω-9) means that it contains 18 carbon atoms, 1 unsaturated bond, and the first double bond is between the 9th and 10th carbons, counting from the methyl end; for example, linolenic acid (18:3, ω-3) means that it contains 18 carbon atoms, 3 unsaturated bonds, and the first double bond is between the 3rd and 4th carbons, counting from the methyl end.

[0049] The fatty acids involved in the present application are specifically: caproic acid C6:0 (i.e. containing 6 carbon atoms and no unsaturated bonds, the same below), caprylic acid C8:0, capric acid C10:0, lauric acid C12:0, myristic acid C14:0, palmitic acid C16:0, stearic acid C18:0, oleic acid C18:1, linoleic acid C18:2, α-linolenic acid C18:3, etc.

[0050] Example 1

[0051] A specific high-quality fat structure cholecystokinin (CCK) releaser, comprising medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids;

[0052] Among them, the medium-chain saturated fatty acid is a saturated fatty acid with 6 to 12 carbon atoms; the long-chain saturated fatty acid is a saturated fatty acid with more than 12 carbon atoms; and the long-chain unsaturated fatty acid is an unsaturated fatty acid with more than 12 carbon atoms.

[0053] Among them, the medium-chain saturated fatty acid is a combination of C6:0, C8:0, C10:0 and C12:0; the long-chain saturated fatty acid is a combination of C14:0, C16:0 and C18:0; the long-chain unsaturated fatty acid is a combination of C18:1, C18:2 and C18:3.

[0054] The medium-chain saturated fatty acids, long-chain saturated fatty acids and long-chain unsaturated fatty acids are derived from coconut powder, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract and fish oil.

[0055] Specifically including: 29.4 parts of coconut powder (all parts by mass below), 44.3 parts of medium chain triglyceride powder, 5 parts of safflower seed oil powder, 4 parts of linseed oil powder, 15 parts of coconut oil powder, 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, and 0.6 parts of white kidney bean extract; all substances are commercially purchased, and coconut powder contains 35% vegetable oil, 6% sodium caseinate, 10% coconut milk, and 49% others.

[0056] The corresponding mass ratio of each component in the obtained composition (such as Figure 1 (shown) are 0.38%, 31.98%, 26.86%, 14.73%, 4.93%, 6.39%, 4%, 3.02%, 2.76% and 4.95% for C6, C8:0, C10:0, C12:0, C14:0, C16:0, C18:0, C18:1, C18:2 and C18:3, respectively.

[0057] In addition to fatty acids, the release agent also includes oligofructose, wolfberry powder and white kidney bean extract;

[0058] Among them, oligofructose is an excellent water-soluble dietary fiber that can effectively reduce serum cholesterol, triglycerides, and free fatty acids, and has a good improvement effect on a series of cardiovascular diseases such as hypertension and arteriosclerosis caused by high blood lipids. Low caloric value, because oligofructose cannot be directly digested and absorbed by the human body, but can only be absorbed and utilized by intestinal bacteria, its caloric value is low, it will not cause obesity, and indirectly has a weight loss effect. It is also a good sweetener for diabetic patients.

[0059] Lycium barbarum has antioxidant, anti-aging and immunomodulatory effects. It reduces triglycerides by increasing the density of proteosterols, thus achieving the effect of lowering blood lipids.

[0060] White kidney bean protein contains a natural α-amylase inhibitor (α-AI), which is a non-competitive inhibitor and is basically not affected by the type of starch. It has the effects of lowering blood sugar, lowering blood lipids and losing weight. Saponins in white kidney beans can reduce fat absorption and promote fat metabolism. The dietary fiber it contains can also speed up the time for food to pass through the intestines and reduce blood lipids. Using it together with other components can better control weight.

[0061] Example 2

[0062] The fatty acid composition is adjusted by adjusting the mass of coconut powder, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, and white kidney bean extract, thereby obtaining release agents with different mass ratios of medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids;

[0063] Specifically include: 28 parts of coconut powder (the following are all weight parts), 39.8 parts of medium chain triglyceride powder, 5 parts of safflower oil powder, 4 parts of linseed oil powder, 19.5 parts of coconut oil powder, 2.5 parts of oligofructose, 0.6 parts of wolfberry powder, 0.6 parts of white kidney bean extract

[0064] The corresponding mass ratios of the release agent components are C6:0, C8:0, C10:0, C12:0, C14:0, C16:0, C18:0, C18:1, C18:2, and C18:3, which are 0.5%, 26%, 21%, 10.29%, 4.91%, 8.1%, 5.8%, 9%, 7.9%, and 6.5%, respectively.

[0065] Example 3

[0066] The fatty acid composition is adjusted by adjusting the mass of coconut powder, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, and white kidney bean extract, thereby obtaining release agents with different mass ratios of medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids;

[0067] Specifically including: 28.7 parts of coconut powder (all parts by mass below), 46 parts of medium-chain triglyceride powder, 5 parts of safflower seed oil powder, 3 parts of linseed oil powder, 15 parts of coconut oil powder, 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, 0.6 parts of white kidney bean extract, and 1 part of fish oil; the corresponding mass ratios of the components in the obtained composition are 0.35%, 30.92%, 25.10%, 10.40%, 3.50%, 10.85%, 3.70%, 8.86%, 3.79%, and 2.57% for C6:0, C8:0, C10:0, C12:0, C14:0, C16:0, C18:0, C18:1, C18:2, and C18:3, respectively.

[0068] The release agents obtained in Examples 1-3 were tested using a kit, and the results showed that they were able to increase the secretion of cholecystokinin, specifically, Example 1 increased by 45%, Example 2 increased by 40%, and Example 3 increased by 42%. At the same time, the red blood cell agglutination activity of Examples 1-3 was 584149-972000U / 100g, and the α-amylase activity was 10300-24388 HUA / 100g; the results showed that good effects could be achieved within the scope of the examples.

[0069] Example 4

[0070] In order to test the effect of the composition obtained from different sources as a release agent, the medium chain triglyceride in Example 1 was replaced by part of peanut oil (medium chain triglyceride: peanut oil = 1:1, i.e. peanut oil replaced 1 / 2 of the mass of medium chain triglyceride), specifically including 29.4 parts of coconut powder (hereinafter all parts by mass g), 22.15 parts of medium chain triglyceride powder, 22.15 parts of peanut oil, 5 parts of safflower seed oil powder, 4 parts of linseed oil powder, 15 parts of coconut oil powder, 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, and 0.6 parts of white kidney bean extract;

[0071] The corresponding mass ratios of the components in the obtained composition are similar to those in Example 1, specifically, C6:0, C8:0, C10:0, C12:0, C14:0, C16:0, C18:0, C18:1, C18:2, and C18:3 are 0.06%, 14.67%, 11.4%, 7.8%, 3.4%, 15.4%, 2.41%, 23.1%, 21.07%, and 0.69%, respectively. The obtained composition is tested using a kit, and the results show that it can increase the secretion of cholecystokinin by 37%, and can increase cholecystokinin under this ratio of fatty acids. Since C8 and C10 are contained in the medium-chain triglycerides, the effect is somewhat reduced relative to Examples 1-3.

[0072] Example 5

[0073] The technical scheme of the present application uses soybean oil instead of coconut powder to obtain a composition as a release agent, specifically 29.4 parts of soybean oil (hereinafter all parts by mass g), 44.3 parts of medium-chain triglyceride powder, 5 parts of safflower seed oil powder, 4 parts of linseed oil powder, 15 parts of coconut oil powder, 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, and 0.6 parts of white kidney bean extract; the corresponding mass ratios of each component in the obtained composition are 0.06%, 30%, 23%, 7.4%, 3%, 4%, 1.5%, 9.1%, 17.44%, and 4.5% for C6:0, C8:0, C10:0, C12:0, C14:0, C16:0, C18:0, C18:1, C18:2, and C18:3, respectively. The secretion of cholecystokinin is 35%, which is less than that of Example 1. This may be because coconut powder contains a certain amount of C6:0, C8:0, C10:0, C18:1, C18:2, and C18:3, which is relatively balanced, and the increase is also conducive to the secretion of cholecystokinin.

[0074] Example 6

[0075] The release agent of Example 1 is prepared into a liquid, specifically comprising the following steps:

[0076] Prepare ingredients: 29.4 parts of coconut powder (the following are all weight parts), 44.3 parts of medium-chain triglyceride powder, 5 parts of safflower seed oil powder, 4 parts of linseed oil powder, 15 parts of coconut oil powder, 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, 0.6 parts of white kidney bean extract

[0077] S21: premix purified water with protein (which may be one or a mixture of plant protein, casein, sodium caseinate, modified starch, gelatin, and whey protein, without special limitation, and plant protein is used as an example in this application), 29.4 parts of coconut powder (hereinafter all in mass parts g), 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, and 0.6 parts of white kidney bean extract, and stir at 35° C. for 20 minutes;

[0078] S22: adding medium chain triglycerides, safflower seed oil, linseed oil and coconut oil to the mixture obtained in S21, and mixing at 45°C and 600 r / min for 20 min;

[0079] S23: Raise the temperature to 65° C., add a stabilizing system (the stabilizing system includes a mixture of one or more of sodium starch octenyl succinate, xanthan gum, sodium carboxymethyl cellulose, gellan gum, locust bean gum, pectin, gelatin, carrageenan, guar gum, soluble soybean polysaccharides, etc., without special limitation, and xanthan gum is used as an example in this application), and stir for 15 minutes;

[0080] S24: pre-sterilization at 90°C for 30 seconds;

[0081] S25: homogenization 280 bar, 55 ° C;

[0082] S26: Add other auxiliary materials, vitamins, minerals, etc. to make up the volume;

[0083] S27: high temperature sterilization, 142℃, 6s;

[0084] S28: Homogenization 100bar;

[0085] S29: Aseptic filling.

[0086] Obtain the cholecystokinin (CCK) releaser and observe the state of the fat globules under a microscope. Figure 2 , it can be observed that the fat globules and other substances are evenly distributed and their properties are relatively stable.

[0087] Comparative Example 1

[0088] Prepare ingredients: 29.4 parts of coconut powder (the following are all weight parts), 44.3 parts of medium-chain triglyceride powder, 5 parts of safflower seed oil powder, 4 parts of linseed oil powder, 15 parts of coconut oil powder, 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, 0.6 parts of white kidney bean extract

[0089] S21: premix purified water with protein (same as in Example 6), 29.4 parts of coconut powder (hereinafter all parts by mass g), 0.2 parts of oligofructose, 0.5 parts of wolfberry powder, and 0.6 parts of white kidney bean extract, and stir at 35° C. for 20 min;

[0090] S22: adding medium chain triglycerides, safflower seed oil, linseed oil and coconut oil to the mixture obtained in S21, and mixing at 45°C and 600 r / min for 20 min;

[0091] S23: Raise the temperature to 65°C, add the stabilizing system (same as in Example 6), and stir for 15 minutes;

[0092] S24: homogenization 240 bar, 55 ° C;

[0093] S25: Add other auxiliary materials, vitamins, minerals, etc. to make up the volume;

[0094] S26: high temperature sterilization, 142℃, 6s;

[0095] S27: 110℃, 30min, sterilization.

[0096] Obtain the cholecystokinin (CCK) releaser and observe the state of the fat globules under a microscope. Figure 3 , obvious fat globules can be seen, which are unevenly distributed.

[0097] Embodiment 7:

[0098] The release agent obtained in Example 6 was combined with conventional nutritional components to obtain a powder product; specifically, it contained 75.173 parts of the release agent obtained in Example 6 (hereinafter all parts by mass g), 15.8 parts of brown rice flour, 6.67 parts of isolated soy protein, 0.9 parts of food additives, 0.3 parts of edible flavors, 0.53 parts of complex vitamins, 0.6 parts of complex minerals, and 0.027 parts of food sweeteners. The food additives included xanthan gum and sodium carboxymethyl cellulose.

[0099] Weigh the composition of Implementation 6, brown rice flour, food additives, edible flavors, complex vitamins, complex minerals, and food sweeteners according to the formula amount and set aside; sieve: all raw materials are passed through a 40-mesh oscillating sieve. Mix: food additives, edible flavors, complex vitamins, complex minerals, and food sweeteners are mixed in equal multiple increments for 15 minutes; then add the remaining raw materials to a three-dimensional mixing tank, mix for a total of 50 minutes, and fill to obtain.

[0100] Mouse testing:

[0101] The experimental animals were Sprague-Dawley (SD) rats, male, SPF (specific pathogen free) clean grade, weight range 130g ± 10g. After the adaptive feeding, they were randomly divided into 2 groups according to body weight, 15 rats were given ordinary feed as blank control group (group A), and 40 rats were given high-calorie model feed. After 3 weeks of feeding, the 40 rats given high-calorie feed were sorted according to weight gain, and 10 obesity-resistant rats with low weight gain were eliminated.

[0102] The 30 obesity-sensitive rats screened were given a high-calorie diet for 3 weeks to establish the model, and the blank control group was given a normal diet at the same time.

[0103] After the modeling period, 30 obesity-sensitive rats were randomly divided into two groups according to their body weight, namely, model control group (group B) and product intervention group (group C). Group A was given ordinary feed, and groups B and C were given high-calorie model feed. Group C was given 5g / Kg of the test sample by gavage every day, and then the animals were free to forage for high-fat feed, and the administration lasted for 6 weeks.

[0104] After the experiment, the subjects were fasted for 12 h, anesthetized with 1% sodium pentobarbital (0.5 ml / 100 g BW), and blood was collected from the femoral artery of the thigh. The blood was left to stand for 30 min at room temperature and centrifuged in a low-temperature centrifuge (3000 rpm, 10 min). The blood cholecystokinin (CCK), triglyceride (TG), cholesterol (TC), low-density lipoprotein (LDL-C) content and the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were immediately measured using a kit. The results were as follows: Figure 2-7Compared with the model group, the CCK content of the animals in the drug-treated group increased, the TG, TC and LDL-C contents decreased, and the activities of ALT and AST decreased. All the differences were significant (P < 0.05). This result shows that the formula food has the effect of regulating CCK secretion and blood lipid levels, and is helpful for the metabolic regulation of obese model animals. The formula food is expected to be used in obese people.

[0105] In summary, it can be seen that the cholecystokinin CCK releaser in the present application is formulated with high-quality fatty acids, which can increase the secretion of cholecystokinin, regulate food intake, reduce food intake, increase satiety, and suppress appetite. The special preparation method of the cholecystokinin CCK releaser increases the stability of the liquid dosage form and reduces the floating of fat globules. It can reduce the triglyceride content in the body, reduce the content of free fatty acids, and significantly and scientifically reduce body weight, and can be used in the fields of weight control, prevention and treatment of overweight and obesity.

[0106] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A specific high-quality fat structure cholecystokinin (CCK) releaser, characterized in that: Including medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids; wherein the medium-chain saturated fatty acids are saturated fatty acids with 6 to 12 carbon atoms; the long-chain saturated fatty acids are saturated fatty acids with more than 12 carbon atoms; and the long-chain unsaturated fatty acids are unsaturated fatty acids with more than 12 carbon atoms.

2. The specific high-quality fat structure cholecystokinin (CCK) releaser according to claim 1, characterized in that: The medium-chain saturated fatty acid is a combination of C6:0, C8:0, C10:0 and C12:0; the long-chain saturated fatty acid is a combination of C14:0, C16:0 and C18:0; and the long-chain unsaturated fatty acid is a combination of C18:1, C18:2 and C18:

3.

3. The specific high-quality fat structure cholecystokinin (CCK) releaser according to claim 1, characterized in that: The medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids are derived from one or a combination of coconut powder, soybean oil, peanut oil, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract, and fish oil.

4. The specific high-quality fat structure cholecystokinin (CCK) releasing agent according to claim 3, characterized in that: The medium-chain saturated fatty acids, long-chain saturated fatty acids and long-chain unsaturated fatty acids are derived from coconut powder, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract and fish oil.

5. The specific high-quality fat structure cholecystokinin (CCK) releasing agent according to claim 4, characterized in that: The mass ratio of the coconut powder, medium-chain triglycerides, safflower seed oil, linseed oil, coconut oil, oligofructose, wolfberry powder, white kidney bean extract and fish oil is 28-29.4:39.8-46:5:3-4:15-19.5:0.2-2.5:0.5-0.6:0.6:0-1; preferably 29.4:44.3:5:4:15:0.2:0.5:0.6:

0.

6. The specific high-quality fat structure cholecystokinin (CCK) releasing agent according to claim 1, characterized in that: The mass ratio of the medium-chain saturated fatty acids, long-chain saturated fatty acids, and long-chain unsaturated fatty acids is 57.79±1-73.95±1:15±1-19±1:10.73±1-23.40±1; Preferably, the mass ratio of the medium-chain saturated fatty acids, the long-chain saturated fatty acids, and the long-chain unsaturated fatty acids is 73.95±1:15±1:10.73±1.

7. The specific high-quality fat structure cholecystokinin (CCK) releasing agent according to claim 2, characterized in that: The mass ratio of C6:0, C8:0, C10:0 and C12:0 in the medium-chain saturated fatty acids is 0.35±1-0.5±1:26±1-31.98±1:21±1-26.86±1:10.29±1-14.73±1; preferably 0.38±1:31.98±1:26.86±1:14.73±1; The mass ratio of C14:0, C16:0 and C18:0 in the long-chain saturated fatty acids is 3.5±1-4.93±1:6.39±1-10.85±1:3.7±1-5.8±1; preferably 4.93±1:6.39±1:4±1; The mass ratio of C18:1, C18:2 and C18:3 in the long-chain unsaturated fatty acids is 3.02±1-9±1:2.76±1-7.9±1:2.57±1-6.5±1; preferably 3.02±1:2.76±1:4.95±1.

8. The specific high-quality fat structure cholecystokinin (CCK) releasing agent according to claim 1, characterized in that: The hemagglutination activity of red blood cells is 584149-972000U / 100g, the α-amylase activity is 10300-24388HUA / 100g; the secretion of cholecystokinin is increased by 35%-45%, preferably by 40%-45%, and preferably by 45%.

9. A method for preparing the specific high-quality fat structure cholecystokinin (CCK) releaser according to any one of claims 1 to 8, characterized in that: Including preparation of powder and liquid dosage forms; Preferably, the preparation into a powder dosage form comprises the following steps: S11: Medium chain triglycerides, safflower seed oil, linseed oil, and coconut oil are obtained by a secondary microencapsulation process to form a powder state containing 70% / 50% fat content or a microencapsulated powder that is entirely embedded in a powder state; Preferably, the preparation process of the microencapsulated powder is as follows: adding antioxidants and stabilizers to medium-chain triglycerides, safflower oil, linseed oil and coconut oil, heating and mixing at 45°C-50°C to obtain a mixed solution A; adding an aqueous wall material to purified water, dissolving at 40-50°C to obtain a mixed solution B, preferably, the aqueous wall material is one of vegetable protein, casein, sodium caseinate, modified starch, gelatin and whey protein; adding the mixed solution A to the mixed solution B, emulsifying with a shearing machine; homogenizing at 20-40MPa for 2-3 times; spray drying to obtain; S12: mixing the microencapsulated powder obtained in S11 with coconut powder, oligofructose, wolfberry powder, and white kidney bean extract for 40 min; Preferably, the preparation into a liquid dosage form comprises the following steps: S21: premix purified water with protein, coconut powder, oligofructose, wolfberry powder and white kidney bean extract at 30°C-35°C and stir for 15-20 minutes; S22: adding medium chain triglycerides, safflower seed oil, linseed oil, coconut oil, or fish oil to the mixture obtained in S21, mixing at 40-45° C. and 600 r / min for 20 min; S23: Raise the temperature to 65°C, add the stabilizing system, and stir for 10-15 minutes; S24: pre-sterilization 85-90℃, 30s; S25: homogenization 280 bar, 55 ° C; S26: Add other auxiliary materials, vitamins and minerals to make up the volume; S27: high temperature sterilization, 141℃-145℃, 4-6s; S28: Homogenization 100bar; S29: Aseptic filling, or sterilization at 110-121℃, 15-30min.

10. Use of the cholecystokinin (CCK) releaser with a specific high-quality fat structure according to any one of claims 1 to 8 in controlling body weight, preventing and treating overweight or obesity, characterized in that: It is used to prepare health products, functional foods, sports nutrition foods, and special medical purpose formula foods.

Citation Information

Patent Citations

  • Cholecystokinin secretion-promoting composition

    CN104661659A

  • Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.

    CN107072274A

  • Compound formula powder with weight loss efficacy and preparation method of compound formula powder

    CN107114674A

  • Fat powder for controlling body weight and preparation method thereof

    CN107373508A

  • Composition suitable for consumption by obese and fat-reducing surgery populations, and preparation method thereof

    CN107712907A